2024
DOI: 10.1002/ehf2.14830
|View full text |Cite
|
Sign up to set email alerts
|

Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design

Jaclyn Carberry,
Mark C. Petrie,
Matthew M.Y. Lee
et al.

Abstract: AimsPatients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium‐glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients.Methods and resultsEMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocard… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 67 publications
0
0
0
Order By: Relevance